Lady Viviana Acosta Castillo
Research Subjects
Lady Viviana Acosta Castillo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Montoya Rendon
Facultad de Ciencias de la Salud, Corporacion Universitaria Alexander von Humboldt, Armenia 630003, Colombia
1 shared publication - Andrés López-Cortés
Cancer Research Group (CRG), Faculty of Medicine, Universidad de las Américas
1 shared publication - Daniel Esteban Castro Valencia
Facultad de Ciencias de la Salud, Corporacion Universitaria Alexander von Humboldt, Armenia 630003, Colombia
1 shared publication - Diego Alexander Lucero-Guanga
Facultad de Salud, Universidad Libre, Cali 760042, Colombia
1 shared publication - Diego Mauricio Gómez-Ramírez
Clínica Imbanaco
1 shared publication - Fabián Darío Arias Rodríguez
Hospital Baca Ortiz
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by MDPI AG in Pathophysiology
- Vol. 33 (2) , 36
From Glycocalyx Shedding to Microvascular Collapse in Sepsis: Endothelial Pathophysiology, Organ Dysfunction, and Mechanistic Biomarkers
Sepsis is a systemic disorder in which infection-induced inflammation progressively disrupts vascular homeostasis and drives organ dysfunction. This review reframes septic pathophysiology as a sequential and self-amplifying process centered on endothelial failure. Early activation of innate immune pathways by pathogen- and damage-associated molecular patterns promotes cytokine release, oxidative stress, and enzymatic degradation of the endothelial glycocalyx. Loss of this protective surface layer exposes endothelial cells to unbuffered inflammatory and mechanical injury, impairing mechanotransduction, increasing leukocyte and platelet adhesion, and destabilizing vascular barrier function. Subsequent disruption of intercellular junctions promotes capillary leakage, tissue edema, and impaired oxygen diffusion, while mitochondrial dysfunction and redox imbalance reduce endothelial repair capacity. In parallel, complement activation, neutrophil extracellular trap formation, platelet–leukocyte interactions, and loss of anticoagulant signaling shift the microvasculature toward a prothrombotic and proinflammatory state. These interconnected mechanisms culminate in microvascular incoherence, characterized by heterogeneous capillary flow, regional hypoxia, impaired oxygen extraction, and progressive organ failure despite apparent restoration of systemic hemodynamics. Within this framework, biomarkers such as syndecan-1, soluble thrombomodulin, angiopoietin-2, von Willebrand factor, and plasminogen activator inhibitor-1 are best interpreted as mechanistic readouts of glycocalyx shedding, endothelial injury, permeability imbalance, and thromboinflammatory activation. Understanding sepsis as an evolving endothelial pathophysiological process provides a coherent framework for integrating inflammation, vascular leakage, hypoxia, coagulation, and organ dysfunction while identifying mechanistic biomarkers that reflect distinct stages of microvascular collapse.
- 29 May 2026
- Published by MDPI AG in Pathophysiology
- Vol. 33 (2) , 36
Open AccessFrom Glycocalyx Shedding to Microvascular Collapse in Sepsis: Endothelial Pathophysiology, Organ Dysfunction, and Mechanistic Biomarkers
Sepsis is a systemic disorder in which infection-induced inflammation progressively disrupts vascular homeostasis and drives organ dysfunction. This review reframes septic pathophysiology as a sequential and self-amplifying process centered on endothelial failure. Early activation of innate immune pathways by pathogen- and damage-associated molecular patterns promotes cytokine release, oxidative stress, and enzymatic degradation of the endothelial glycocalyx. Loss of this protective surface layer exposes endothelial cells to unbuffered inflammatory and mechanical injury, impairing mechanotransduction, increasing leukocyte and platelet adhesion, and destabilizing vascular barrier function. Subsequent disruption of intercellular junctions promotes capillary leakage, tissue edema, and impaired oxygen diffusion, while mitochondrial dysfunction and redox imbalance reduce endothelial repair capacity. In parallel, complement activation, neutrophil extracellular trap formation, platelet–leukocyte interactions, and loss of anticoagulant signaling shift the microvasculature toward a prothrombotic and proinflammatory state. These interconnected mechanisms culminate in microvascular incoherence, characterized by heterogeneous capillary flow, regional hypoxia, impaired oxygen extraction, and progressive organ failure despite apparent restoration of systemic hemodynamics. Within this framework, biomarkers such as syndecan-1, soluble thrombomodulin, angiopoietin-2, von Willebrand factor, and plasminogen activator inhibitor-1 are best interpreted as mechanistic readouts of glycocalyx shedding, endothelial injury, permeability imbalance, and thromboinflammatory activation. Understanding sepsis as an evolving endothelial pathophysiological process provides a coherent framework for integrating inflammation, vascular leakage, hypoxia, coagulation, and organ dysfunction while identifying mechanistic biomarkers that reflect distinct stages of microvascular collapse.
- Open Access
- 3 September 2024
- Published by Asociación Colombiana de Hepatología in Hepatología
- Vol. 5 (3) , 230-237
Miopatía por micofenolato posterior a trasplante hepático: reporte de caso
Las miopatías inducidas por medicamentos son una causa relativamente frecuente de debilidad muscular aguda. En muchos casos, los síntomas comienzan poco después del inicio de la medicación causante; sin embargo, el diagnóstico puede ser difícil debido a la polifarmacia o a la asociación inicial de los síntomas con otras patologías. Esto puede provocar un retraso en la retirada del medicamento, lo cual es fundamental para el tratamiento. Se presenta el caso de un paciente de 62 años de edad con antecedentes de hepatocarcinoma, quien presentó debilidad muscular aguda en el posoperatorio de un trasplante hepático temprano. Se documentó una asociación excepcional con miopatía inducida por micofenolato. Tras suspender este fármaco, el paciente recuperó completamente la fuerza muscular, confirmando así el diagnóstico. De hecho, este caso es el segundo reportado en la literatura médica sobre miopatía inducida por micofenolato.
- 3 September 2024
- Published by Asociación Colombiana de Hepatología in Hepatología
- Vol. 5 (3) , 230-237
Open AccessMiopatía por micofenolato posterior a trasplante hepático: reporte de caso
Las miopatías inducidas por medicamentos son una causa relativamente frecuente de debilidad muscular aguda. En muchos casos, los síntomas comienzan poco después del inicio de la medicación causante; sin embargo, el diagnóstico puede ser difícil debido a la polifarmacia o a la asociación inicial de los síntomas con otras patologías. Esto puede provocar un retraso en la retirada del medicamento, lo cual es fundamental para el tratamiento. Se presenta el caso de un paciente de 62 años de edad con antecedentes de hepatocarcinoma, quien presentó debilidad muscular aguda en el posoperatorio de un trasplante hepático temprano. Se documentó una asociación excepcional con miopatía inducida por micofenolato. Tras suspender este fármaco, el paciente recuperó completamente la fuerza muscular, confirmando así el diagnóstico. De hecho, este caso es el segundo reportado en la literatura médica sobre miopatía inducida por micofenolato.